SHJBF Stock Chart & Stats
$3.25
--
Market closed
$3.25
--
Day’s Range― - ―
52-Week Range$2.12 - $4.54
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.00
Market Cap
$4.43B
Enterprise Value$19.88K
Total Cash (Recent Filing)$3.70B
Total Debt (Recent Filing)$5.91B
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding260,295,700
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.39Price Target Upside4.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$415.73M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth indicates improving commercial adoption of the company’s medicines and expanding demand. Continued top-line momentum can provide greater operating leverage as the portfolio scales and commercialization investments mature.
Strong Gross MarginsHigh gross margins suggest attractive product-level economics and meaningful value captured from commercialized therapies. If maintained, they provide a foundation for future operating leverage once research, development, and selling costs become more efficient.
Improving Loss TrajectoryNarrowing losses indicate progress toward better financial efficiency, even though profitability has not been reached. Further improvement could reduce funding needs and increase the likelihood that revenue growth translates into sustainable earnings over time.
Bears Say
Persistent Operating LossesOngoing operating and net losses show that strong product-level margins are not yet covering research, development, commercialization, and corporate costs. Persistent losses delay self-funded growth and leave profitability dependent on further scale or cost reductions.
Substantial Cash BurnNegative operating and free cash flow indicates that the business is not currently funding operations and investment internally. Continued cash burn may require external financing or balance-sheet resources, increasing dilution, funding, and execution risks.
Rising LeverageThe sharp increase in leverage materially reduces financial flexibility while returns remain negative. Higher debt can constrain investment in the pipeline and increase balance-sheet pressure if losses and cash burn persist, particularly during periods requiring additional funding.
Shanghai Junshi Biosciences Co., Ltd. Class H News
SHJBF FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was $2.12 and its highest was $4.54 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is $4.43B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Oct 23, 2026 which is in 53 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported $0.003 earnings per share for the quarter.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Undervalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of $0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in SHJBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.39 (4.20% Upside)
$3.39 (4.20% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
SHJBF Stock 12 Month Forecast
Average Price Target
$3.39
▲(4.20% Upside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
2.43% Mutual Funds
― Other Institutional Investors
94.69% Public Companies and
Individual Investors